Aurinia Pharmaceuticals Inc (AUPH) - Total Liabilities
Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has total liabilities worth $177.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aurinia Pharmaceuticals Inc (AUPH) investment intensity to see how much of total assets are deployed in long-term investments.
Aurinia Pharmaceuticals Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how Aurinia Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AUPH total assets.
Aurinia Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
USA | $37.44 Billion |
|
Greif Bros Corporation
NYSE:GEF
|
USA | $2.57 Billion |
|
Titan Wind Energy Suzhou
SHE:002531
|
China | CN¥18.05 Billion |
|
Scandic Hotels Group AB (publ)
ST:SHOT
|
Sweden | Skr50.40 Billion |
|
Ziraat Gayrimenkul Yatirim Ortakligi AS
IS:ZRGYO
|
Turkey | TL21.59 Billion |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
Germany | €2.72 Billion |
|
TAV Havalimanlari Holding
IS:TAVHL
|
Turkey | TL3.45 Billion |
|
Xinjiang Joinworld Co Ltd
SHG:600888
|
China | CN¥7.50 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Aurinia Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AUPH equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aurinia Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual total liabilities of Aurinia Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $170.26 Million | -1.68% |
| 2024-12-31 | $173.17 Million | +1.80% |
| 2023-12-31 | $170.11 Million | +160.00% |
| 2022-12-31 | $65.42 Million | +1.79% |
| 2021-12-31 | $64.28 Million | +14.96% |
| 2020-12-31 | $55.91 Million | +117.54% |
| 2019-12-31 | $25.70 Million | -22.79% |
| 2018-12-31 | $33.29 Million | +38.10% |
| 2017-12-31 | $24.10 Million | +14.52% |
| 2016-12-31 | $21.05 Million | +54.71% |
| 2015-12-31 | $13.60 Million | +87.07% |
| 2014-12-31 | $7.27 Million | -26.11% |
| 2013-12-31 | $9.84 Million | +56.75% |
| 2012-12-31 | $6.28 Million | -20.63% |
| 2011-12-31 | $7.91 Million | +101.05% |
| 2010-12-31 | $3.93 Million | -16.98% |
| 2009-12-31 | $4.74 Million | -74.78% |
| 2008-12-31 | $18.79 Million | +31.82% |
| 2007-12-31 | $14.25 Million | +36.12% |
| 2006-12-31 | $10.47 Million | -12.69% |
| 2005-12-31 | $11.99 Million | +33.65% |
| 2004-12-31 | $8.97 Million | +52.33% |
| 2003-12-31 | $5.89 Million | +88.80% |
| 2002-12-31 | $3.12 Million | +75.33% |
| 2001-12-31 | $1.78 Million | +47.12% |
| 2000-12-31 | $1.21 Million | +27.22% |
| 1999-12-31 | $950.74K | -60.53% |
| 1998-12-31 | $2.41 Million | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more